文献速递白血病

FLT3抑制剂lestaurtinib联合化疗治疗新诊断KMT2A重排婴儿急性淋巴细胞白血病:COG AALL0631试验

FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
PubMed 文献 · Leukemia · 2021-02-23

该研究在KMT2A重排婴儿ALL中评估诱导后化疗联合lestaurtinib是否改善无事件生存(EFS)。总体3年EFS在联合组与单纯化疗组无差异,但FLT3抑制药效学达标且白血病细胞体外敏感的患者EFS显著提高。

要点

  • 总体加用lestaurtinib未改善KMT2A重排婴儿ALL的3年EFS。
  • FLT3抑制药效学达标者EFS显著优于未达标者。
  • 体外对FLT3抑制敏感者EFS显著优于耐药者。

核心结论

  • 在KMT2A重排婴儿ALL中,诱导后加用lestaurtinib未总体改善3年EFS。
  • FLT3抑制药效学达标且白血病细胞体外敏感的患者可从lestaurtinib联合化疗中获益。
  • 患者选择和药效学指导的剂量递增可能提高FLT3抑制在该人群的疗效。

研究设计与样本

  • 儿童肿瘤协作组(COG)AALL0631试验,KMT2A重排婴儿ALL诱导后随机接受化疗或化疗联合lestaurtinib。
  • 联合组67例,单纯化疗组54例;开展FLT3抑制药效学(PD)和体外敏感性(EVS)检测。

主要发现

  • 联合组与单纯化疗组3年EFS分别为36±6%与39±7%(p=0.67),无显著差异。
  • 联合组中,FLT3抑制达标与未达标者EFS分别为59±10%与28±7%(p=0.009)。
  • 联合组中,体外敏感与耐药者EFS分别为52±8%与5±5%(p<0.001)。

关键数值与推荐

  • FLT3抑制药效学(PD)将患者分为抑制达标与未达标。
  • FLT3抑制体外敏感性(EVS)将白血病原始细胞分为敏感与耐药。
  • 3年EFS在联合组与单纯化疗组分别为36±6%与39±7%(p=0.67)。

临床怎么用

  • 对KMT2A重排婴儿ALL,不应常规在诱导后加用lestaurtinib而不进行患者选择。
  • 治疗中应检测FLT3抑制药效学和体外敏感性,以识别可能获益的患者。
  • 对药效学未达标者,可考虑药效学指导的剂量递增以提高FLT3抑制程度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infants with KMT2A-rearranged acute lymphoblastic leukemia (KMT2A-r ALL) have a poor prognosis. KMT2A-r ALL overexpresses FLT3, and the FLT3 inhibitor (FLT3i) lestaurtinib potentiates chemotherapy-induced cytotoxicity in preclinical models. Children's Oncology Group (COG) AALL0631 tested whether adding lestaurtinib to post-induction chemotherapy improved event-free survival (EFS). After chemotherapy induction, KMT2A-r infants received either chemotherapy only or chemotherapy plus lestaurtinib. Correlative assays included FLT3i plasma pharmacodynamics (PD), which categorized patients as inhibited or uninhibited, and FLT3i ex vivo sensitivity (EVS), which categorized leukemic blasts as sensitive or resistant. There was no difference in 3-year EFS between patients treated with chemotherapy plus lestaurtinib (n = 67, 36 ± 6%) vs. chemotherapy only (n = 54, 39 ± 7%, p = 0.67). However, for the lestaurtinib-treated patients, FLT3i PD and FLT3i EVS significantly correlated with EFS. For FLT3i PD, EFS for inhibited/uninhibited was 59 ± 10%/28 ± 7% (p = 0.009) and for FLTi EVS, EFS for sensitive/resistant was 52 ± 8%/5 ± 5% (p < 0.001). Seventeen patients were both inhibited and sensitive, with an EFS of 88 ± 8%. Adding lestaurtinib did not improve EFS overall, but patients achieving potent FLT3 inhibition and those whose leukemia blasts were sensitive FLT3-inhibition ex vivo did benefit from the addition of lestaurtinib. Patient selection and PD-guided dose escalation may enhance the efficacy of FLT3 inhibition for KMT2A-r infant ALL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Brown PA, Kairalla JA, Hilden JM, et al. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. Leukemia. 2021. PMID: 33623141. doi:10.1038/s41375-021-01177-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。